Calendario›UPB›UPB-101
UPB-101
Safety and Biologic Impact (Pharmacodynamics) of Repeated Injections and Increasing Amounts of UPB-101 in Asthmatics
Ensayo de Upstream Bio, Inc. en Asma.
Más ensayos de: Asma.
- Fase
- Fase 1
- Estado
- Completado
- Participantes
- 32
- Centros
- 4
- Fin del objetivo primario
- ago 2023
previstos
fecha real
Qué significa cada fase y cada estado.
Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en jul 2022.
Qué mide
Number of Treatment-emergent Adverse Events and Serious Adverse Events (del registro, en inglés) (del inicio a las 24 semanas)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThe goals of this clinical study were to assess the safety, tolerability, blood levels, and disease impact of UPB-101 when given to adults with mild asthma. Eligible participant were consecutively assigned to 1 of 3 to 5 planned treatment groups. Each treatment group consisted of 8 individuals, six of whom will received active drug (UPB-101) and 2 who received placebo. Neither the study doctors nor the participants knew which participants were assigned to active study drug and which were assigned to placebo. The study was performed at 4 experienced research sites in the United Kingdom.
Más ensayos de UPB
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| Verekitug | Fase 2 | En marcha, sin reclutar | sep 2027 (prevista) |
| Verekitug | Fase 2 | En marcha, sin reclutar | oct 2027 (prevista) |
| Verekitug | Fase 2 | Completado | dic 2025 (real) |
| Verekitug · VIBRANT | Fase 2 | Completado | jul 2025 (real) |
| UPB-101 | Fase 1 | Completado | abr 2023 (real) |
Todos los de UPB, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT05448651), actualizada en dic 2024.